Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/KREBSBIO stock hub

NSE/KREBSBIO has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/KREBSBIOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.3B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/KREBSBIO

In the news

Latest news · NSE/KREBSBIO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 24.9P50 32.4P75 45.7

Trailing P/En/a

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC-15.1

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/KREBSBIO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

153

Groups with data

Currency

INR

Showing 153 of 153 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	202
Employees Change	11%
Employees Change Percent	5.76
Enterprise value	INR 3.5B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE268B01013
Last refreshed	2026-05-10
Market cap	INR 1.3B
Price	INR 60.2
Price currency	INR
Rev Per Employee	1,139,752.48x
Sector	Healthcare
Sic	2833
Symbol	nse/KREBSBIO
Website	https://krebsbiochem.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-17.67%
EV Earnings	-15.34x
EV/Sales	15.23x
P/B ratio	-0.8x
P/S ratio	5.62x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-70.96%
EBITDA Margin	-42.96%
Gross margin	76.83%
Gross Profit	INR 176.9M
Gross Profit Growth	-54.05%
Gross Profit Growth Q	-28.4%
Gross Profit Growth5 Y	53.48%
Net Income	INR -228.6M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Pretax Margin	-99.23%
Profit Margin	-99.3%
Profit Per Employee	INR -1.1M
Roa5y	-8.82
ROCE	-30.09
ROIC	-15.12

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-17.55%
Cagr3y	-4.88%
Cagr5y	-13.63%
EPS Growth Quarters	1
EPS Growth Years	0
Revenue Growth	-53.19x
Revenue Growth Q	-36.57x
Revenue Growth Years	0x
Revenue Growth3 Y	-26.85x
Revenue Growth5 Y	-14.9x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	INR 1.7B
Cash	INR 1.5M
Current Assets	INR 97.8M
Current Liabilities	INR 1.1B
Debt	INR 2.2B
Equity	INR -1.6B
Interest Coverage	-2.41
Liabilities	INR 3.3B
Long Term Assets	INR 1.6B
Long Term Liabilities	INR 2.2B
Net Cash	INR -2.2B
Net Cash By Market Cap	INR -171
Tangible Book Value	INR -1.6B
Tangible Book Value Per Share	INR -75.45
WACC	4.02

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.09
Net Working Capital	INR -455.1M
Quick ratio	0
Working Capital	INR -1B

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.03%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-17.53%
200-day SMA	66.2
3Y total return	-13.94%
50-day SMA	55.55
50-day SMA vs 200-day SMA	50under200
5Y total return	-51.94%
All Time High	227.9
All Time High Change	-73.58%
All Time High Date	2021-12-31
All Time Low	38.33
All Time Low Change	57.06%
All Time Low Date	2026-03-30
ATR	3.25
Beta	0.45
Ch YTD	-12.8
High	62.31
High52	113.5
High52 Date	2025-06-09
High52ch	-46.96%
Low	60.2
Low52	38.33
Low52 Date	2026-03-30
Low52ch	57.06%
Ma50ch	8.36%
Price vs 200-day SMA	-9.07%
RSI	54.9
RSI Monthly	44.66
RSI Weekly	47.53
Sharpe ratio	-0.24x
Sortino ratio	-0.27
Total Return	0.03%
Tr YTD	-12.8
Tr1m	-2.59%
Tr1w	1.35%
Tr3m	4.86%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR -163.4M
Operating margin	-70.96

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	4,066,004%
Shares Insiders	26.68%
Shares Institutions	0%
Shares Qo Q	0.04%
Shares Yo Y	-0.03%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	6,078.45x
Bv Per Share	-74.59
Ch1m	-2.59
Ch1w	1.35
Ch1y	-17.53
Ch3m	4.86
Ch3y	-13.94
Ch5y	-51.94
Ch6m	-12.36
Change	-2.9%
Change From Open	-2.9
Close	62
Days Gap	0
Depreciation Amortization	64,474,750
Dollar Volume	15,351
Earnings Date	2026-05-21
EBIT	INR -163.4M
EBITDA	INR -98.9M
EPS	INR -10.6
F Score	0
Fiscal Year End	March
Founded	1,991
Income Tax	INR 153,000
Is Primary Listing	0
Last Earnings Date	2026-02-09
Last Report Date	2025-12-31
Ma150	62.71
Ma150ch	-4%
Ma20	60.44
Ma20ch	-0.4%
Next Earnings Date	2026-05-21
Open	62
Position In Range	0
Ppne	1,435,405,000
Price Date	2026-05-08
Relative Volume	0.02x
Revenue	230,230,000x
Tax By Revenue	0.07x
Tr6m	-12.36%
Volume	255

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does NSE/KREBSBIO pay a dividend?

Capital-return profile for this ticker.

Performance

NSE/KREBSBIO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/KREBSBIO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+0.0%

Share of float held by funds and institutions

Insider ownership

+26.7%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.0%

Negative means the company is buying back shares.

Technical

NSE/KREBSBIO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

54.9

Neutral momentum band

Price vs 200-day MA

-9.1%

50/200-day relationship not available

Beta (5Y)

0.45

Less volatile than the market

Sharpe ratio

-0.24

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/KREBSBIO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/KREBSBIO stock rating?

nse/KREBSBIO is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/KREBSBIO analysis?

The full report lives at /stocks/nse/KREBSBIO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/KREBSBIO?

The latest report frames nse/KREBSBIO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/KREBSBIO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.